Literature DB >> 21232965

Pharmacophore models based studies on the affinity and selectivity toward 5-HT1A with reference to α1-adrenergic receptors among arylpiperazine derivatives of phenytoin.

Jadwiga Handzlik1, Ewa Szymańska, Krystyna Nędza, Monika Kubacka, Agata Siwek, Szczepan Mogilski, Jarosław Handzlik, Barbara Filipek, Katarzyna Kieć-Kononowicz.   

Abstract

The study is focused on (2-alkoxy)phenylpiperazine derivatives of 1-(2-hydroxy-3-(4-arylpiperazin-1-yl)propyl)-5,5-diphenylimidazolidine-2,4-dione with alkyl or ester substituents at N3 of hydantoin ring, as well as a new designed and synthesized series of compounds with a free N3H group or N3-acetic acid terminal fragment. The compounds were assessed on their affinity for 5-HT(1A) and α(1)-adrenoceptors and evaluated in functional bioassays for antagonistic properties. Classical molecular mechanics (MMFFs force field, MCMM, MacroModel) and DFT methods (B3LYP functional, Gaussian 0.3) were used to investigate 3D structure of the compounds. SAR analysis was based on two pharmacophore models, the one described by Barbaro et al. for α(1)-adenoceptor antagonist and the model of Lepailleur et al. for 5-HT(1A) receptor ligands. All compounds exhibited significant to moderate affinities for 5-HT(1A) receptors in nanomolar range (7-610nM). The highest activity (7nM) and selectivity (17.38) for 5-HT(1A) was observed for 1-(3-(4-(2-ethoxyphenyl)piperazin-1-yl)-2-hydroxypropyl)-3-methyl-5,5-diphenylimidazolidine-2,4-dione (13a). Among new synthesized compounds 1-(2-hydroxy-3-(4-(2-methoxyphenyl)piperazin-1-yl)propyl)-5,5-diphenylimidazolidine-2,4-dione hydrochloride (20a) displayed the highest affinity (16.6nM) and selectivity (5.72) for α(1)-AR.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21232965     DOI: 10.1016/j.bmc.2010.11.051

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  3 in total

Review 1.  Phenytoin: 80 years young, from epilepsy to breast cancer, a remarkable molecule with multiple modes of action.

Authors:  Jan M Keppel Hesselink; David J Kopsky
Journal:  J Neurol       Date:  2017-01-12       Impact factor: 4.849

2.  In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson's Disease.

Authors:  Agostinho Lemos; Rita Melo; Antonio Jose Preto; Jose Guilherme Almeida; Irina Sousa Moreira; Maria Natalia Dias Soeiro Cordeiro
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

3.  Development of Bis-cyclic Imidazolidine-4-one Derivatives as Potent Antibacterial Agents.

Authors:  Minghui Wang; Ruixuan Gao; Mengmeng Zheng; Peng Sang; Chunpu Li; En Zhang; Qi Li; Jianfeng Cai
Journal:  J Med Chem       Date:  2020-09-24       Impact factor: 7.446

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.